These two new “weight loss” drugs have been getting a lot of attention: Semaglutide, a GLP1 (glucagon like peptide 1) receptor agonist, and Tirzepatide, a dual GLP1, and GIP (glucose-dependent insulinotropic polypeptide) agonist. GLP1 and GIP are both peptides that...
